News GSK enters PARP space with TESARO acquisition GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).
News Tesaro stock rockets as rumours of Roche takeover abound Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.
Views & Analysis ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c... Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
Oncology Clovis' Rubraca close to EU approval in ovarian cancer CHMP backs conditional approval for PARP drug
News Tesaro and Roche to combine drugs in bladder cancer trials Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK